AstraZeneca advances its ambition to revolutionise cancer care with new data across its diverse, industry-leading portfolio and pipeline at the IASLC 2024 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, 7 to 10 September 2024 and the European Society for Medical Oncology (ESMO) Congress, 13 to 17 September 2024.

Across the two meetings, more than 130 abstracts will feature 17 approved and potential new medicines from AstraZeneca including five Presidential Symposia and 41 oral presentations.

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "The presentations across these two congresses advance our long-term strategy to revolutionise cancer care. We will show results from our computational pathology platform at WCLC which we are using across our antibody drug conjugate portfolio to develop predictive biomarkers to enhance patient selection and improve outcomes for patients. We will also share data on the use of our TROP2 antibody drug conjugate datopotamab deruxtecan in combination with Imfinzi in early-stage lung cancer, a promising first look at clinical activity from two of our own pipeline antibody drug conjugates and important progress for our next-generation immunotherapies."

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: "Our data featured at WCLC and ESMO will exhibit AstraZeneca's progress in advancing several of the biggest trends transforming cancer treatment today and potentially in the future. Positive results for Imfinzi from the NIAGARA trial in muscle-invasive bladder cancer will show the importance of integrating perioperative immunotherapy in this setting, and data for datopotamab deruxtecan and Enhertu in several lung cancer settings will highlight how antibody drug conjugates have the potential to replace traditional chemotherapy approaches in many cancer settings."  

Key trend: early intervention and transforming outcomes in early-stage disease

A Presidential Symposium at ESMO will showcase the results from the NIAGARA Phase III trial of Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before cystectomy (surgery to remove the bladder) followed by Imfinzi as adjuvant monotherapy in patients with muscle-invasive bladder cancer. High-level results for this Imfinzi-based regimen showed a statistically significant and clinically meaningful event-free survival (EFS) and overall survival (OS) benefit, making it the first perioperative immunotherapy regimen to show extended survival in bladder cancer in a Phase III trial.

In lung cancer, several presentations at both meetings will reinforce the Company's progress toward moving treatment to earlier stages of disease. These include:

• A late-breaking Presidential Symposium at WCLC that will feature efficacy and safety data from the NeoCOAST-2 Phase II platform trial. This trial evaluates Imfinzi in multiple novel combinations, before and after surgery, in patients with resectable, early-stage non-small cell lung cancer (NSCLC), including a combination with datopotamab deruxtecan. Results will build on the proven efficacy of perioperative Imfinzi as demonstrated in the AEGEAN Phase III trial, which was recently approved in the US.

• A late-breaking oral presentation at WCLC sharing results from the second interim analysis of the AEGEAN Phase III trial of perioperative Imfinzi-based treatment in patients with resectable early-stage (IIA-IIIB) NSCLC. The data include EFS in subgroups of patients who did or did not achieve pathologic complete response, as well as new disease-free survival and OS results. An additional late-breaking oral presentation at ESMO sharing AEGEAN circulating tumour DNA (ctDNA) data will provide insights on how patients respond to treatment.

• A late-breaking mini-oral presentation at WCLC highlighting patient-reported outcomes from the ADRIATIC Phase III trial of Imfinzi in patients with limited-stage small cell lung cancer whose disease did not progress on concurrent chemoradiotherapy (CRT). Additionally, an oral presentation at ESMO will share outcomes in key patient subgroups.

• A mini-oral presentation at ESMO of results from the LAURA Phase III trial including analyses of central nervous system metastases and distant progression with Tagrisso (osimertinib) in unresectable, Stage III EGFRm NSCLC after CRT. Additional data from LAURA will include a safety analysis at WCLC and a poster presentation at ESMO of efficacy and safety results in a cohort of patients in China.

Key trend: novel ADCs replacing systemic chemotherapy

A late-breaking Presidential Symposium at WCLC of exploratory results from the application of AstraZeneca's proprietary computational pathology platform, quantitative continuous scoring (QCS), to tissue samples collected in TROPION-Lung01 will demonstrate the potential of TROP2, as measured by QCS, as a predictive biomarker for datopotamab deruxtecan.

Additionally, a late-breaking oral presentation will showcase OS data from the TROPION-Lung01 Phase III trial evaluating datopotamab deruxtecan in patients with previously treated locally advanced or metastatic NSCLC. In May (https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-improved-os-in-nonsquamous-lung-cancer.html), high-level results showed that datopotamab deruxtecan demonstrated a clinically meaningful OS improvement versus docetaxel, the current standard-of-care chemotherapy, in patients with advanced nonsquamous NSCLC previously treated with immunotherapy or targeted therapy.

Also, at WCLC, an oral presentation will highlight efficacy and safety data from Part 1 of the DESTINY-Lung03 Phase Ib trial of Enhertu (trastuzumab deruxtecan) in patients with previously treated HER2-overexpressing unresectable, locally advanced or metastatic NSCLC, building on data from the DESTINY-Lung01 Phase II trial.

At ESMO, a late-breaking oral presentation from the DESTINY-Breast12 Phase IIIb/IV trial of Enhertu in patients with previously treated metastatic HER2-positive breast cancer with and without brain metastases will showcase the potential benefits of this important medicine in this patient population. Additionally, an oral presentation of the DESTINY-Gastric03 Phase Ib/II trial will feature safety and efficacy data for the combination of Enhertu, chemotherapy and pembrolizumab as a 1st-line treatment in HER2-positive gastric and gastroesophageal junction (GEJ) cancers.

A mini-oral presentation at ESMO will highlight first results from the endometrial and ovarian cancer cohorts of the TROPION-PanTumour03 Phase II trial of datopotamab deruxtecan.

Several presentations at ESMO will showcase the strength of the Company's emerging proprietary antibody drug conjugate (ADC) technology. These include:

• A proffered paper presentation sharing dose escalation results from the BLUESTAR Phase I/IIa trial of B7-H4 ADC AZD8205 in patients with B7-H4-expressing advanced solid tumours. B7-H4 is a promising ADC target which is highly expressed in several solid tumours. AZD8205 is the first ADC bearing a novel proprietary topoisomerase I inhibitor (TOP1i) linker payload to enter the clinic. Robust AZD8205 anti-tumour response has previously been reported in B7-H4-expressing preclinical models across multiple tumour types.

• A poster presentation sharing dose escalation results from the FONTANA Phase I/IIa first-in-human trial of AZD5335 demonstrating clinical activity, favourable pharmacokinetic and manageable safety profiles in patients with platinum-resistant recurrent ovarian cancer. This ADC has a FRα-targeting antibody linked to a proprietary TOP1i warhead. A robust anti-tumour response has previously been reported in FRα-expressing preclinical models that are resistant to another FRα ADC with a microtubule inhibitor warhead.

Key trend: advancing next wave of immunotherapy agents

Several presentations will underscore the Company's commitment to advancing its comprehensive bispecific antibody programme:

• A poster presentation sharing the first report of overall response rate and safety data from Substudy 2 of the GEMINI-Gastric Phase II trial, testing rilvegostomig (AZD2936), a PD-1/TIGIT bispecific immune checkpoint inhibitor, plus chemotherapy as a 1st-line treatment in patients with HER2-negative, locally advanced unresectable or metastatic GEJ cancers.
• Additionally, two late-breaking oral presentations at WCLC will highlight efficacy and safety results from the ARTEMIDE-01 Phase I trial of rilvegostomig in patients with metastatic NSCLC, as well as from a Phase Ib/II trial of volrustomig (PD-1/CTLA-4) in combination with chemotherapy in the 1st-line for patients with advanced NSCLC. 

Key trend: powerful combinations to attack cancer from multiple angles

In addition to the novel regimens evaluated in DESTINY-Lung03, DESTINY-Gastric03 and NeoCOAST-2, we are assessing further combination treatment approaches below to improve outcomes for patients:

• A late-breaking, Presidential Symposium presentation for Tagrisso from the externally sponsored FLOWERS Phase II trial of Tagrisso with or without Orpathys (savolitinib) in patients with EGFRm advanced NSCLC with MET aberrations will evaluate the potential of this novel combination to overcome mechanisms of resistance in the 1st-line setting.

• Two late-breaking mini-oral presentations at WCLC will highlight new data from the FLAURA2 Phase III trial of Tagrisso plus chemotherapy in advanced EGFRm NSCLC, including efficacy in patients with high tumour burden and those whose cancers harbour TP53 mutations at baseline.

• A mini-oral presentation featuring five-year OS data from an exploratory analysis of the HIMALAYA Phase III trial of STRIDE (Single Tremelimumab Regular Interval Durvalumab) in patients with unresectable liver cancer who have not received prior systemic therapy and are not eligible for localised treatment. These data represent the longest survival follow-up reported to date for a Phase III trial in this setting.

Collaboration in the scientific community is critical to improving outcomes for patients. AstraZeneca is collaborating with Daiichi Sankyo Company Limited to develop and commercialise Enhertu and datopotamab deruxtecan, collaborating with MSD (Merck & Co., Inc. in the US and Canada) to develop and commercialise Lynparza (olaparib), and collaborating with HUTCHMED to develop and commercialise Orpathys. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902. AstraZeneca obtained full oncology rights to monalizumab from Innate Pharma in October 2018 through a co-development and commercialisation agreement initiated in 2015.

Key AstraZeneca presentations during IASLC WCLC 2024[1]

Lead Author Abstract Title Presentation details (PDT)
Antibody
drug
conjugates
Garassino, Normalized membrane ratio of TROP2 by Abstract #PL02.11
MC quantitative continuous scoring is Presidential 1
predictive of clinical outcomes in 8 September 2024 
TROPION-Lung 01  9:22 AM
Sands, J Datopotamab deruxtecan vs docetaxel Abstract #OA08.03
in patients with non-small cell lung Oral Session
cancer: final overall survival from 9 September 2024
TROPION-Lung01 10:47 AM
Planchard, Trastuzumab deruxtecan monotherapy in Abstract #OA16.05
D pretreated HER2-overexpressing Oral Session
nonsquamous non-small cell lung 10 September 2024 
cancer: DESTINY-Lung03 part 1 1:52 PM
Immuno
-oncology
Cascone, T Neocoast-2: Efficacy and safety of Abstract #PL02.07
neoadjuvant durvalumab (D) + novel Presidential 1 
anticancer agents + CT and adjuvant D 8 September 2024
± novel agents in resectable NSCLC   8:56 AM
Hiltermann, Efficacy and safety of rilvegostomig, Abstract #OA11.03
TJN an anti-PD-1/TIGIT bispecific, for Oral Session
CPI-naïve metastatic NSCLC with PD-L1 9 September 20242:02 PM
1-49% or ≥50%
Heymach, JV Perioperative durvalumab for Abstract #OA13.03
resectable NSCLC (R-NSCLC): updated Oral Session
outcomes from the phase 3 AEGEAN 9 September 2024
trial 3:32 PM
Spigel, DR Volrustomig + platinum doublet Abstract #OA11.04
chemotherapy (CTx) in first-line non Oral Session
-small cell lung cancer (NSCLC): 9 September 2024
phase 1b trial update 2:12 PM
Novello, S Patient-reported outcomes (PROs) with Abstract #MA17.04
consolidation durvalumab versus Mini Oral Session
placebo following cCRT in limited 10 September 2024
-stage SCLC: ADRIATIC 3:07 PM
Skoulidis, TRITON: Tremelimumab + durvalumab + Abstract #P4.11D.01
F  chemotherapy (CT) vs pembrolizumab + Poster Session
CT in mNSCLC with STK11, KEAP1 and/or 9 September 2024
KRAS mutations 6:30 PM
Tumour
drivers and
resistance
Yang, J Osimertinib with or without Abstract #PL04.10
savolitinib as 1L in de novo MET Presidential 2
aberrant, EGFRm advanced NSCLC (CTONG 9 September 2024
2008): a phase II trial 9:17 AM
Kato, T Osimertinib after definitive CRT in Abstract #OA12.03
unresectable stage III EGFR-mutated Oral Session
NSCLC: safety outcomes from the phase 9 September 2024
3 LAURA study 2:02 PM
Yang, JC FLAURA2: Resistance, and impact of Abstract #MA12.03
baseline TP53 alterations in patients Mini Oral Session
treated with 1L osimertinib ± 10 September 2024
platinum-pemetrexed 1:32 PM
Valdiviezo, FLAURA2: Impact of tumor burden on Abstract #MA12.04
N outcomes of 1L osimertinib ± Mini Oral Session
chemotherapy in patients with EGFR 10 September 2024
-mutated advanced NSCLC 1:37 PM

[1] 59 abstracts at IASLC WCLC 2024 will feature AstraZeneca medicines and pipeline molecules

Key AstraZeneca presentations during ESMO Congress 2024[2]

Lead Author Abstract Title Presentation details
(CEST)
Antibody
drug
conjugates
Datopotamab
deruxtecan
Oaknin, A Datopotamab Abstract #714MO Mini Oral
deruxtecan (Dato Session15 September 2024
-DXd) in patients 2:45 PM
with endometrial
(EC) or ovarian
cancer (OC):
results from the
phase 2 TROPION
-PanTumor03 study 
Trivedi, MS Rates of Abstract #LBA15
pathologic Mini Oral Session
complete response 14 September 2024
(pCR) after 11:20 AM
datopotamab
deruxtecan (dato)
plus durvalumab
(durva) treatment
strategy in the
neoadjuvant
setting: results
from the I-SPY 2.2
trial
Khoury, K Rates of Abstract #LBA16
pathologic Mini Oral Session
complete response 14 September 2024
(pCR) after 11:25 AM
datopotamab
deruxtecan (dato)
in the neoadjuvant
setting: results
from the I-SPY 2.2
trial
Rugo, HS Exposure-adjusted Abstract #431P
incidence rates Poster Session
(EAIRs) of adverse 16 September 2024
events (AEs) from
the TROPION
-Breast01 study of
datopotamab
deruxtecan (Dato
-DXd) vs
investigator's
choice of
chemotherapy (ICC)
in patients (pts)
with pretreated,
inoperable/metastat
ic HR+/HER2-
breast cancer (BC)
Pons Datopotamab Abstract #1312P
-Tostivint, deruxtecan (Dato Poster Session
E -DXd) vs docetaxel 14 September 2024
(DTX) in patients
(pts) with
advanced
nonsquamous (NSQ)
non-small cell
lung cancer
(NSCLC) with brain
metastases (mets):
results from
TROPION-Lung01
Enhertu
Lin, N Trastuzumab Abstract #LBA18
deruxtecan (T-DXd) Proffered Paper Session
in patients (pts) 13 September 2024
with HER2+ 4:00 PM
advanced/metastatic
breast cancer
(mBC) with or
without brain
metastases (BM):
DESTINYBreast-12
primary results
Janjigian, Trastuzumab Abstract #1401O
YY deruxtecan (T-DXd) Proffered Paper Session
monotherapy and 14 September 2024
combinations in 9:25 AM
patients (pts)
with
advanced/metastatic
HER2-positive
(HER2+)
esophageal,
gastric or
gastroesophageal
junction
adenocarcinoma
(GEJA): DESTINY
-Gastric03 (DG-03)
Hu, X Effects of Abstract #LBA22
trastuzumab Mini Oral Session
deruxtecan (T-DXd) 15 September 2024
vs choice of 9:10 AM
chemotherapy (TPC)
on patient
-reported outcomes
(PROs) in hormone
receptor-positive,
HER2-low or HER2
-ultralow
metastatic breast
cancer (mBC):
results from
DESTINY-Breast06
Ueno, NT Exploratory Abstract #432P Poster
biomarker analysis Session
of trastuzumab 16 September 2024
deruxtecan versus
treatment of
physician's choice
in HER2-low,
hormone
receptor-positive
metastatic breast
cancer in DESTINY
-Breast04
AZD8205
Meric Initial results Abstract #606O
-Bernstam, from a first-in Proffered Paper Session
F -human study of 13 September 2024
the B7-H4-directed 4:50 PM
antibody-drug
conjugate (ADC)
AZD8205 (puxitatug
samrotecan) in
patients with
advanced/metastatic
solid tumors
AZD5335
Shapira Initial results Abstract #754P Poster
-Frommer, from a first-in Session
R  -human study of 14 September 2024
AZD5335, a folate
receptor α (FRα)
-targeted antibody
-drug conjugate,
in patients (pts)
with platinum
-resistant
recurrent ovarian
cancer (PRROC) 
Immuno
-oncology
Powles, TB A randomized phase Abstract #LBA5
3 trial of Presidential 215
neoadjuvant September 2024
durvalumab plus 5:14 PM
chemotherapy
followed by
radical cystectomy
and adjuvant
durvalumab in
muscle-invasive
bladder cancer
(NIAGARA)
Tomasini, P Precision immuno Abstract #LBA8
-oncology for Presidential 316
advanced non-small September 2024
cell lung cancer 5:24 PM
(NSCLC) patients
with PD-(L)1
inhibitors
resistance
(PIONeeR): a phase
Ib/IIa clinical
trial targeting
identified
resistance
pathways
Senan, S Durvalumab (D) as Abstract #LBA81
consolidation Proffered Paper Session
therapy in limited 13 September 2024
-stage SCLC (LS 2:25 PM
-SCLC): outcomes
by prior
concurrent
chemoradiotherapy
(cCRT) regimen and
prophylactic
cranial
irradiation (PCI)
use in the
ADRIATIC trial
Reck, M Associations of Abstract #LBA49
ctDNA clearance Mini Oral Session
(CL) during 15 September 2024
neoadjuvant Tx 10:40 AM
with pathological
response and event
-free survival
(EFS) in pts with
resectable NSCLC
(R-NSCLC):
expanded analyses
from AEGEAN
Riccardo Circulating tumor Abstract #LBA51
Filippi, A DNA (ctDNA) Mini Oral Session
dynamics and 15 September 2024
treatment 10:45 AM
responses in
chemotherapy
-ineligible
patients (pts)
with unresectable
Stage III NSCLC
from the phase 2
DUART trial
Rimassa, L Five-year overall Abstract #947MO
survival (OS) and Mini Oral Session
OS by tumour 16 September 2024
response measures 9:25 AM
from the phase 3
HIMALAYA study of
tremelimumab plus
durvalumab in
unresectable
hepatocellular
carcinoma (uHCC)
Rivera First-line Abstract #1422P
Herrero, F rilvegostomig Poster Session
(rilve) + 16 September 2024
chemotherapy (CTx)
in patients (pts)
with HER2-negative
(HER2-) locally
advanced
unresectable or
metastatic gastric
cancers: first
report of GEMINI
-Gastric substudy
2
Blank, SV Durvalumab + Abstract #732P
carboplatin/paclita Poster Session
xel (CP) followed 14 September 2024
by durvalumab ±
olaparib as a
first-line
treatment for
endometrial cancer
(EC): progression
-free survival
(PFS) by clinical
factors in DUO-E
Tumour
drivers and
resistance
Lu, S Osimertinib (osi) Abstract #1241MO
after definitive Mini Oral Session
chemoradiotherapy 16 September 2024 
(CRT) in 2:45 PM
unresectable (UR)
stg III EGFRm
NSCLC: analyses of
CNS and distant
progression from
the phase 3 LAURA
study
Dong, X Osimertinib (osi) Abstract #1248P
after definitive Poster Session
chemoradiotherapy 14 September 2024 
(CRT) in
unresectable stage
III epidermal
growth factor
receptor-mutated
(EGFRm) NSCLC:
LAURA China cohort
analysis

[2] 79 abstracts at ESMO Congress 2024 will feature AstraZeneca medicines and pipeline molecules

Notes

AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on social media @AstraZeneca (https://www.linkedin.com/company/astrazeneca/).

Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).